

# Engineering Biosensors with Extended, Narrowed, or Arbitrarily Edited Dynamic Range

Alexis Vallée-Bélisle,<sup>†,‡,#</sup> Francesco Ricci,<sup>||,⊥,#</sup> and Kevin W. Plaxco<sup>\*,†,‡,§</sup>

<sup>†</sup>Department of Chemistry and Biochemistry, <sup>‡</sup>Center for Bioengineering, and <sup>§</sup>Interdepartmental Program in Biomolecular Science and Engineering, University of California, Santa Barbara, California 93106, United States

<sup>||</sup>Dipartimento di Scienze e Tecnologie Chimiche, University of Rome, Tor Vergata, Via della Ricerca Scientifica, 00133 Rome, Italy


<sup>⊥</sup>Consorzio Interuniversitario Biostrutture e Biosistemi, Rome, Italy

**S** Supporting Information

**ABSTRACT:** Biomolecular recognition has long been an important theme in artificial sensing technologies. A current limitation of protein- and nucleic acid-based recognition, however, is that the useful dynamic range of single-site binding typically spans an 81-fold change in target concentration, an effect that limits the utility of biosensors in applications calling for either great sensitivity (a steeper relationship between target concentration and output signal) or the quantification of more wide-ranging concentrations. In response, we have adapted strategies employed by nature to modulate the input–output response of its biorecognition systems to rationally edit the useful dynamic range of an artificial biosensor. By engineering a structure-switching mechanism to tune the affinity of a receptor molecule, we first generated a set of receptor variants displaying similar specificities but different target affinities. Using combinations of these receptor variants (signaling and nonsignaling), we then rationally extended (to 900000-fold), narrowed (to 5-fold), and edited (three-state) the normally 81-fold dynamic range of a representative biosensor. We believe that these strategies may be widely applicable to technologies reliant on biorecognition.

The versatility of biomolecular recognition supports the high-affinity, high-specificity recognition of an enormous range of molecular targets. This observation has motivated decades of research aimed at harnessing biological recognition in molecular sensing technologies, many of which have become critical tools in the modern diagnostic arsenal.<sup>1–3</sup>

Despite these positive attributes, biological recognition exhibits a potentially significant limitation: the physics of single-site binding produces a hyperbolic dose–response curve for which the useful dynamic range spans a fixed change in target concentration. Specifically, the transition from 10% to 90% site occupancy requires a fixed 81-fold span of target concentration<sup>4,5</sup> (Figure 1, top). This fixed dynamic range complicates (or even precludes) the use of biosensors in many applications. Clinically relevant HIV loads, for example, typically vary over more than 5 orders of magnitude,<sup>6</sup> dwarfing the dynamic range associated with single-site binding. This same 81-fold dynamic range also renders biosensors poorly suited for applications requiring the very precise measurement



**Figure 1.** Using nature’s tricks to extend or narrow the fixed dynamic ranges of single-site receptors. Top: The dynamic range of sensors with a single-site receptor spans an 81-fold range of target concentration over which the sensor response transits from 10% to 90% of its signal output. Middle: This useful dynamic range can be extended by combining multiple receptors differing in their affinity for the same target. Bottom: The dynamic range can be narrowed, producing a very steep, “ultrasensitive” dose–response curve via a sequestration mechanism that employs a high-affinity nonactive depletant receptor. The depletant (white) serves as a “sink” that sequesters free target molecules until it is saturated. With a concentration of the depletant above the dissociation constant of the receptor,  $K_D$ , an increase in target concentration above this depletant concentration will generate a threshold response, leading to an ultrasensitive response.<sup>9</sup>

of target concentration. For example, the therapeutic indices of many drugs, including cyclosporine and the aminoglycosides,<sup>7</sup> are often less than an order of magnitude. The clinical measurement of these drugs thus requires a degree of precision that is often difficult to achieve with a device that requires a 81-


Received: October 29, 2011

Published: December 26, 2011

fold change in concentration in order to transition from 10% to 90% of signal saturation.

Faced with the above limitations, evolution has invented a number of simple mechanisms by which the normally fixed dynamic range of single-site binding can be extended, narrowed, or otherwise “edited” to better ensure the survival of an organism.<sup>4,5,8–10</sup> For example, in order to create extended—or even more complex, three-state—dose-response sensing systems, evolution often employs pairs of closely related receptors (recognition elements) differing in affinity (Figure 1, middle).<sup>8,11</sup> Nature has likewise invented methods to narrow the dynamic range of single-site binding, so as to create steep, ultrasensitive outputs to ensure robust responses to small changes in target concentration. The sequestration mechanism (Figure 1, bottom),<sup>9</sup> for example, employs a high-affinity, nonsignaling receptor to prevent the accumulation of free target until the total target concentration surpasses the concentration of this “depletant” (the sink is saturated). This produces a threshold response in which further target addition leads to a dramatic increase in the relative concentration of free target, generating an apparent “all-or-none” response from a second, lower affinity—but signaling—receptor. Despite their simplicity, however, and the ubiquity with which nature employs them, these strategies have seen little (extended dynamic range, refs 12–15) if any (narrowing and more complex editing) application in artificial technologies. Indeed, the majority of past efforts have focused on kinetic—rather than thermodynamic—approaches to altering the dynamic range.<sup>16,17</sup> In response, here we demonstrate the utility of these equilibrium strategies in optimizing the dynamic range of synthetic biosensors.

The mechanisms we have employed require the availability of matched sets of receptors varying in affinity (Figure 1). The only approaches that have been reported to date to broaden the dynamic range of a biosensor, however, have employed receptors varying in affinity via alterations of the binding site itself,<sup>12–15</sup> which affects specificity. Combination of such receptors therefore exhibit varying specificity across their dynamic range. We have circumvented this by generating receptors that retain identical specificities. We did so by engineering a conformational switching mechanism into the receptor (Figure 2) via the stabilization of an alternative



**Figure 2.** The introduction of a switching mechanism allows ready tuning of the affinity of receptors. This can be realized by stabilizing an alternative, nonbinding state.<sup>21</sup> The apparent affinity of the modified receptor can be rationally tuned by altering the equilibrium constant between the two states,  $K_S$  (Figure S2). Using this strategy we have tuned the affinity of DNA molecular beacons by up to 4 orders of magnitude by varying the GC base pair content in their stems.<sup>19</sup> Such modification does not alter the receptor’s binding interface (shown in red) and does not alter specificity (see Figure S2).


“nonbinding” state. By tuning the switching equilibrium constant of such a receptor we can alter its apparent affinity without altering the specific interactions that it forms with its target.<sup>18,19</sup> A similar strategy is often used by nature to decrease

affinity without altering specificity; an example is the intrinsically unfolded proteins, which reduce their affinity (by coupling binding to an unfavorable folding event) without altering their specificity (the binding site itself is not altered).<sup>20</sup>

Using the structure-switching approach we have generated a set of six receptors with affinities spanning 4 orders of magnitude (Figure 2). Specifically, we have fabricated a set of molecular beacons,<sup>3</sup> a widely employed DNA stem-loop fluorescent biosensor for the detection of specific nucleic acid sequences (Figure S1a), that differ only in the stability of their “nonbinding” conformation (i.e., stability of their double-stranded stem).<sup>19</sup> As expected, each of these variants retains the classic hyperbolic binding curve (an 81-fold dynamic range) expected for single-site binding, producing dissociation constants ranging from 0.012 to 128  $\mu\text{M}$  (Figure 2 and Table S1). Likewise, as expected, all six receptors display similar discrimination between their correct target and a mutant target differing by a single nucleotide (Figure S2).

In order to extend the useful dynamic range of this biosensor, we have combined two or more receptors differing in affinity (Figure 1, middle). To do so, we first performed simulations to define the *difference* in affinity that maximizes the linear (on a  $\log[\text{concentration}]$  plot) range of the paired receptors (Figure S3). These simulations indicate that combining receptors differing by 100-fold in affinity produces a wide yet still highly log-linear dynamic range. If the difference in the affinities of the two receptors climbs above 100-fold, significant deviations from linearity are observed at intermediate target concentrations (Figure S3). Of note, however, a limitation related to the use of a structure-switching signaling mechanism is that the signal gain of individual receptors also degrades if the switch is too unstable (see Table S1 and Figure S4a).<sup>19</sup> More precisely, as the nonbinding state becomes less stable (as the switching equilibrium constant,  $K_S$ , rises above 0.05), the fraction of receptor in the binding-competent signaling state in the absence of target becomes significant, reducing both the total fluorescence change and signal gain (relative fluorescence change) at saturating target concentrations.<sup>19</sup> The naïve approach of combining receptors in equimolar concentrations would thus lead to deviations from ideal behavior. Fortunately, we can correct for this effect by adjusting the molar ratios of the two receptors (Figure S4b). For example, our molecular beacons 1GC (83% of the maximum fluorescent change, Table S1) and 3GC (maximum fluorescence change), which differ in affinity by exactly 100-fold, can be combined in a ratio of 59/41 to create a sensor with an extended, 8100-fold dynamic range of nearly perfect log-linearity ( $R^2 = 0.995$ ) and 9-fold signal gain (Figure 3). Moreover, the modified sensor maintains the same specificity across its entire dynamic range (Figure S5).

While 8100-fold represents the broadest log-linear dynamic range that can be achieved using just two receptors, we can broaden the dynamic range still further by adding additional variants. A potential challenge, however, is that the precision with which we can control receptor affinity is not perfect, and thus, again, nonstoichiometric ratios of variants are required to produce good log-linear behavior. Here too, however, simulations can be used to determine the optimal mixing ratios (Figure S4c). To demonstrate this we have designed a mixture of four receptors, which includes two molecular beacons (0GC and 5GC) differing in affinity by more than 10000-fold (Table S1). Combining this with optimized concentrations of two molecular beacons of intermediate affinity (2GC and 3GC), we obtain a sensor with 3.6-fold




**Figure 3.** We can extend and edit the dynamic range of sensors by combining sets of receptors differing in affinity. Extended dynamic range: We have extended the useful 81-fold dynamic range of a traditional molecular beacon to 8100-fold by combining two beacons differing by 100-fold in affinity. We have also combined four molecular beacons to achieve a 900000-fold log-linear range (see Figure S4 for optimization of the receptor ratios). Three-state dynamic range: By combining molecular beacons differing more than 500-fold in affinity (see Figure S3), we can generate more complex “three-state” dose–response sensors, which “push” their useful dynamic range toward the extremes at the cost of poorer sensitivity at intermediate concentrations. Shown here is a mixture of two molecular beacons differing in affinity by a factor of  $\sim 12000$ , which together generate an intermediate 100-fold concentration plateau over which the sensor response is flat. Of note, by using the structure-switching mechanism to modulate receptor affinity, all of these sensors share a common specificity profile across the entirety of their dynamic ranges (see Figure S5).

signal gain and a log-linear range ( $R^2 = 0.995$ ) that, at  $\sim 900000$ -fold, is more than 4 orders of magnitude greater than that of any single molecular beacon (Figure 3). Again, this “wider” sensor maintains a constant specificity profile across its entire dynamic range (Figure S5).

Other applications could benefit from yet more complex dose–response curves. It may, for example, prove beneficial in some circumstances to “trade-off” sensitivity (the ability to measure small changes in concentration) within a window of useful concentrations (e.g., the clinically relevant concentration range of a drug) in order to achieve enhanced precision above or below the “appropriate” concentration range. That is, in some applications it may prove useful to achieve a “three-state” dynamic range that “pushes” the useful dynamic range of a sensor toward its extremes at the cost of poorer precision at intermediate concentrations. Such response can be realized by combining receptors with affinities differing by more than 500-fold (Figure S3). Here we used two molecular beacons, 0GC and 5GC, differing in affinity by 12000-fold (Table S1). The resultant sensor is highly sensitive to excursions of the target concentrations either above or below an intermediate 100-fold span of concentrations at the cost of exhibiting little sensitivity over the intermediate range (Figure 3).

For still other applications the 81-fold dynamic range of single-site binding is too broad, limiting our ability to achieve sufficiently precise measurements of target concentration. In response we have also narrowed the dynamic range of our sensor (larger change in output for a given change in target

concentration) using sequestration (Figure 1, bottom). In this mechanism, which is thought to underlie the extraordinary sensitivity of many genetic networks,<sup>9,10</sup> the concentration of free target is suppressed using a high-affinity, nonsignaling receptor, termed the “depletant”, that acts as a “sink” (Figure 1, bottom).<sup>9</sup> When the total target concentration surpasses the depletant concentration, this sink is saturated and a threshold response is achieved in which any further increase in total target drastically raises the relative concentration of free target. This, in turn, activates a second, lower affinity—but signaling—receptor generating a “pseudo-cooperative”<sup>22</sup> dose–response curve in which the output signal rises much more rapidly with increasing target concentration than would occur in the absence of a depletant. We have adapted the sequestration mechanism to molecular beacons by employing the nonswitching (and thus high-affinity), nonsignaling, linear DNA as the depletant (Figure 4a). Using this depletant we have narrowed the



**Figure 4.** Narrowing and tuning the dynamic range of sensors using the sequestration mechanism. (a) We can narrow the dynamic range of a sensor, i.e., producing a very steep, “ultrasensitive” dose–response curve, via a sequestration mechanism (gray box) that employs a high-affinity nonsignaling “depletant”.<sup>9</sup> This depletant acts as a “sink”, keeping the concentration of free target molecules low until the sink is saturated. (b) With a concentration of depletant,  $[\text{dep}]$ , above the dissociation constant of the receptor,  $K_D^{\text{sig}}$ , the receptor in target concentration above this  $[\text{dep}]$  will generate a threshold response, leading to an ultrasensitive response. (c) Conveniently, the dynamic range of this narrowed dynamic range can be arbitrarily shifted to respond to higher target concentration by increasing the concentration of depletant. Of note, nonswitching receptor variants are a useful source of depletant, as these bind more tightly than the corresponding structure-switching receptors.

dynamic range of a traditional molecular beacon by more than an order of magnitude (Figure 4b). Specifically, by employing a relatively low affinity molecular beacon (1GC) as our signaling moiety and a 30-fold excess of the higher affinity depletant, we have created an ultrasensitive sensor that transitions from 10% to 90% of its output over a 5-fold range of concentrations (Figure 4b). Moreover, the center of the narrowed dynamic range can be arbitrarily “tuned” by simply varying the depletant concentration (Figure 4c).

Here we have employed several naturally occurring strategies to rationally extend, narrow, and otherwise edit the dynamic range of an artificial biosensor. These strategies are simple and versatile and only require the availability of sets of receptors differing in affinity. Using a structure-switching approach to tune the affinity of our receptor without modifying its specificity,<sup>21</sup> and using a combination of signaling and nonsignaling receptors, we have rationally extended (to 900000-fold), narrowed (to 5-fold), and edited (three-state)

(Figure S6) the useful dynamic range of a widely employed biosensor for the detection of specific DNA sequences.

The approaches described here could, in principle, be applied to a wide range of biomolecules, provided that these can be engineered to support the requisite structure-switching mechanism.<sup>21</sup> Fortunately, rational strategies have been developed for the design of structure-switching aptamers or aptazymes<sup>21,23–25</sup> and for the tuning of their dynamic range.<sup>19,26–29</sup> Rational and semirational strategies are also available to engineer such switching mechanisms into proteins.<sup>18,21,30–36</sup> Loh and co-workers, for example, have demonstrated a generic strategy to design novel protein-based switches, termed “alternate frame folding”, which uses a duplication of a portion of a protein’s sequence to stabilize an alternative, nonbinding, circularly permuted conformation.<sup>32</sup> Alternatively, proteins and nucleic acids can be engineered to undergo folding-induced conformational changes via the introduction of destabilizing mutations (typically remote from the target binding site so as to ensure that specificity is retained), which pushes the folding equilibrium toward the nonbinding, unfolded state and thus reduces the protein’s binding affinity.<sup>35</sup>

The strategies proposed here could prove of use in many biorecognition-based applications. “Smarter” fluorescent probes for real-time *in vivo* imaging, for example, could be created to display optimized dynamic ranges adapted to specific biologically relevant concentration ranges. Molecular beacons, for example, which are often used for the real-time monitoring of specific RNA *in vivo*,<sup>37</sup> could be used in a “mixture” format to precisely detect either very small or very large concentration variations of specific RNA targets. A similar strategy may be also adapted for genetically encoded fluorescent sensors (e.g., calcium reporter<sup>34</sup> and zinc sensor<sup>38</sup>), by coexpressing various active and/or inactive variants of these sensors *in vivo*. Finally, the strategies presented here may be applicable to all fields relying on biorecognition. For example, similar approaches could be employed to implement highly optimized input–output response in binding-activated biomaterials, nanomachines, drug-release devices, or synthetic biology systems.

## ■ ASSOCIATED CONTENT

### ■ Supporting Information

Supporting table, methods, figures, and complete ref 20. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

kwp@chem.ucsb.edu

### Author Contributions

<sup>#</sup>These authors contributed equally to this work.

## ■ ACKNOWLEDGMENTS

The authors acknowledge Jacob Somerson, Anna Simon, and Camille Lawrence for helpful discussions on the manuscript. This work was supported by the NIH through grant R01AI076899. A.V.B. is a Fonds de Recherche du Québec Nature et Technologies (FRQNT) Fellow. F.R. is thankful to the Italian Ministry of University and Research (MIUR) through the project FIRB “Futuro in Ricerca”.

## ■ REFERENCES

- (1) Engvall, E.; Perlman, P. *Immunochemistry* **1971**, *8*, 871.
- (2) Renart, J.; Reiser, J.; Stark, G. R. *Proc. Natl. Acad. Sci. U.S.A.* **1979**, *76*, 3116.
- (3) Tyagi, S.; Kramer, F. R. *Nat. Biotechnol.* **1996**, *14*, 303.
- (4) Koshland, D. E. Jr.; Goldbeter, A.; Stock, J. B. *Science* **1982**, *217*, 220.
- (5) Ferrell, J. E. Jr. *Trends Biochem. Sci.* **1996**, *21*, 460.
- (6) Carpenter, C. C.; Fischl, M. A.; Hammer, S. M.; Hirsch, M. S.; Jacobsen, D. M.; Katzenstein, D. A.; Montaner, J. S.; Richman, D. D.; Saag, M. S.; Schooley, R. T.; Thompson, M. A.; Vella, S.; Yeni, P. G.; Volberding, P. A. *JAMA* **1997**, *277*, 1962.
- (7) Goodman, L. S.; Gilman, A.; Hardman, J. G.; Gilman, A. G.; Limbird, L. E. *Goodman & Gilman's the pharmacological basis of therapeutics*, 9th ed.; McGraw-Hill Health Professions Division: New York, 1996.
- (8) Bhattacharya, S.; Bunick, C. G.; Chazin, W. J. *Biochim. Biophys. Acta* **2004**, *1742*, 69.
- (9) Buchler, N. E.; Louis, M. J. *Mol. Biol.* **2008**, *384*, 1106.
- (10) Young, M. W.; Kay, S. A. *Nat. Rev. Genet.* **2001**, *2*, 702.
- (11) Linse, S.; Helmersson, A.; Forsen, S. *J. Biol. Chem.* **1991**, *266*, 8050.
- (12) Marvin, J. S.; Corcoran, E. E.; Hattangadi, N. A.; Zhang, J. V.; Gere, S. A.; Hellinga, H. W. *Proc. Natl. Acad. Sci. U.S.A.* **1997**, *94*, 4366.
- (13) Yamazaki, T.; Kojima, K.; Sode, K. *Anal. Chem.* **2000**, *72*, 4689.
- (14) Drabovich, A. P.; Okhonin, V.; Berezovski, M.; Krylov, S. N. *J. Am. Chem. Soc.* **2007**, *129*, 7260.
- (15) Andersson, O.; Nikkinen, H.; Kanmert, D.; Enander, K. *Biosens. Bioelectron.* **2009**, *24*, 2458.
- (16) Wang, J. *Chem. Rev.* **2008**, *108*, 814.
- (17) Wang, Z.; Lee, J. H.; Lu, Y. *Adv. Mater.* **2008**, *20*, 3263.
- (18) Marvin, J. S.; Hellinga, H. W. *Nat. Struct. Biol.* **2001**, *8*, 795.
- (19) Vallée-Bélisle, A.; Ricci, F.; Plaxco, K. W. *Proc. Natl. Acad. Sci. U.S.A.* **2009**, *106*, 13802.
- (20) Dunker, A. K.; et al. *J. Mol. Graph. Model.* **2001**, *19*, 26.
- (21) Vallée-Bélisle, A.; Plaxco, K. W. *Curr. Opin. Struct. Biol.* **2010**, *20*, 518.
- (22) Ricci, F.; Vallée-Bélisle, A.; Plaxco, K. W. *PLoS Comput. Biol.* **2011**, *7*, e1002171.
- (23) Hamaguchi, N.; Ellington, A.; Stanton, M. *Anal. Biochem.* **2001**, *294*, 126.
- (24) Lau, P. S.; Coombes, B. K.; Li, Y. *Angew. Chem., Int. Ed.* **2010**, *49*, 7938.
- (25) Sefah, K.; Phillips, J. A.; Xiong, X.; Meng, L.; Van Simaey, D.; Chen, H.; Martin, J.; Tan, W. *Analyst* **2009**, *134*, 1765.
- (26) Liu, J.; Lu, Y. *J. Am. Chem. Soc.* **2003**, *125*, 6642.
- (27) Chen, X.; Ellington, A. D. *PLoS Comput. Biol.* **2009**, *5*, e1000620.
- (28) Xiang, Y.; Tong, A.; Lu, Y. *J. Am. Chem. Soc.* **2009**, *131*, 15352.
- (29) Beisel, C. L.; Smolke, C. D. *PLoS Comput. Biol.* **2009**, *5*, e1000363.
- (30) Golyanskiy, M. V.; Koay, M. S.; Vinckenborg, J. L.; Merckx, M. *Chembiochem* **2011**, *12*, 353.
- (31) Guntas, G.; Mansell, T. J.; Kim, J. R.; Ostermeier, M. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 11224.
- (32) Stratton, M. M.; Mitrea, D. M.; Loh, S. N. *ACS Chem. Biol.* **2008**, *3*, 723.
- (33) Strickland, D.; Yao, X.; Gawlak, G.; Rosen, M. K.; Gardner, K. H.; Sosnick, T. R. *Nat. Methods* **2010**, *7*, 623.
- (34) Palmer, A. E.; Giacomello, M.; Kortemme, T.; Hires, S. A.; Lev-Ram, V.; Baker, D.; Tsien, R. Y. *Chem. Biol.* **2006**, *13*, 521.
- (35) Kohn, J. E.; Plaxco, K. W. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 10841.
- (36) Mizoue, L. S.; Chazin, W. J. *Curr. Opin. Struct. Biol.* **2002**, *12*, 459.
- (37) Mhlanga, M. M.; Tyagi, S. *Nat. Protoc.* **2006**, *1*, 1392.
- (38) Vinckenborg, J. L.; Nicolson, T. J.; Bellomo, E. A.; Koay, M. S.; Rutter, G. A.; Merckx, M. *Nat. Methods* **2009**, *6*, 737.